Trial Profile

A phase II trial of MRX 34 in patients with renal cell carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRX 34 (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Sponsors Mirna Therapeutics

Most Recent Events

01 Apr 2016 New trial record
29 Mar 2016 According to a Mirna Therapeutics media release, this trial is expected to initiate by the end of 2016.
29 Mar 2016 According to a Mirna Therapeutics media release, the company plans to provide a clinical update from these studies in the second half of 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com